Medical Management of Restrictive Eating Disorders in Adolescents and Young Adults
Abstract
The medical provider plays an important role in the management of adolescents and young adults (AYAs) with restrictive eating disorders (EDs), including anorexia nervosa (AN), atypical anorexia nervosa, and avoidant/restrictive food intake disorder. The focus of this article is the medical management of AYAs with restrictive EDs, which can be performed by a number of different medical providers, including pediatricians, family physicians, internists, nurse practitioners, and, in some countries, psychiatrists. This position paper clarifies the role of the medical provider in diagnosing and managing restrictive EDs in AYAs and advocates for consistent standardized terminology for clinical and research purposes when describing the degree of malnutrition and differentiating the degree of malnutrition from treatment goal weight. Boys and men with restrictive EDs are frequently underdiagnosed and may have distinct clinical presentations with important implications for medical management. The medical and psychological complications of AYAs with avoidant/restrictive food intake disorder and atypical anorexia nervosa can be just as severe as those with AN. Scientific evidence supports weight restoration as an important early goal of treatment in AN. Most AYAs with restrictive EDs can be treated as outpatients, and family-based therapy is a first-line outpatient psychological treatment for adolescents with AN. Recent research has demonstrated that inpatient refeeding protocols can…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.